Rochelle Nazarian
Family · Danvers, MANPI 1417986860
Payments from drug & device makers
Across 1,047 payments — averaging $29.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shield Therapeutics Inc$7K
- AbbVie$5K
- AstraZeneca$4K
- Amgen$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- plus $11K from 49 others
What the payments were for
- Speaking & faculty fees$3,30011%
- Travel & lodging$2,6329%
- Food & beverage$24,64480%
- Education$1060%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,682 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 64 | $65,801 |
| TrulicityDulaglutide | 39 | $41,399 |
| JanuviaSitagliptin Phosphate | 32 | $39,716 |
| OzempicSemaglutide | 35 | $34,282 |
| JardianceEmpagliflozin | 29 | $33,040 |
| LinzessLinaclotide | 28 | $26,199 |
| EliquisApixaban | 14 | $17,418 |
| MyrbetriqMirabegron | 19 | $14,725 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $11,173 |
| BrilintaTicagrelor | 13 | $4,773 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 109 | $3,607 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,807 |
| Clobetasol Propionate | 35 | $2,684 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $2,323 |
| Lidocaine | 13 | $1,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $4,037 | $70,57477 claims |
| Lilly USA, LLCTrulicity | $1,227 | $41,39939 claims |
| MerckJanuvia | $300 | $39,71632 claims |
| Novo NordiskOzempic | $1,357 | $34,28235 claims |
| Boehringer IngelheimJardiance | $578 | $33,04029 claims |
| AbbVieLinzess | $4,948 | $26,19928 claims |
| PfizerEliquis | $444 | $17,41814 claims |
| Astellas Pharma US IncMyrbetriq | $424 | $14,72519 claims |
| GSKBreo Ellipta | $566 | $11,17320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.
Other family in Danvers
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Courtney NixonAmherst$81K
- Elizabeth WalshBrighton$80K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
- Leslie StefanowiczDartmouth$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.